Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
SINGAPORE, Jan 28, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has tested 3F Antimicrobial Fragrance which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world's population.
The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. Experiments were performed at ATCC as a custom service within its High Containment Laboratory under BioSafety Level 3 conditions. ATCC is a premier biological materials and information resource and standards organization with expertise in handling and experimentation on dangerous pathogens such as MTB.
Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F Antimicrobial Fragrance. "3F works by taking advantage and exploiting the bacterial or viral sophisticated communication system called quorum sensing.
"In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.The 3F project was designed to provide a solution for open environment defence strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective."
"As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB," said Dr. Manzour Hazbon, ATCC Senior Scientist. "This fragrance is very effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases."
Mr Chan Heng Fai, Executive Chairman of SeD said, "We are excited about the potential of this breakthrough in 3F Antimicrobial, and Global BioLife will step up in its continued efforts to provide cutting edge research into real solutions for global healthcare problems."
Dr. Roscoe M. Moore Jr, former Senior Assistant Surgeon General of the U.S. and highly-regarded public health expert who serves as Senior Scientific Adviser to Global BioLife, says "I'm excited about 3F's potential to address a global epidemic by providing safe and versatile protection layers."
"Tuberculosis is a global priority and Global BioLife's solution will help save lives on a global scale." Dr. Moore also served as Epidemic Intelligence Service Officer with the U.S. Center for Disease Control and Prevention, and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration.
Also advising Global BioLife is Lieutenant Colonel William H. Lyerly Jr., a former Scientific Professional (ST) with the U.S. Government Civil Service and retired U.S. Army Medical Service Corps Officer with an extensive medical background including disaster relief, development, biodefense, interagency and civilmilitary cooperation and teaching.
"As TB's person-to-person spread requires only a small number of bacteria and transmission is most rapid in confined spaces, 3F efficacy is especially promising. And as multidrug-resistant TB continues a global health crisis and security threat, 3F's environmental intervention represents an effective and less-costly TB control strategy in high-transmission areas worldwide."
Global Biolife has partnered with Destum Inc to license its 3F technology to global manufacturers and distributers. 3F Mosquito, unlike repellents such as DEET, was developed as an additive to laundry detergents and lotions for layered protection against mosquitos. 3F Antimicrobial was developed as an additive for sprays, filters and dispersal systems in hospitals, transit and open areas to protect against bacteria and viruses.
Global BioLife (GBLI) is 70%-held by Global BioMedical, owned by Singapore BioMedical Ltd, owned by Singapore eDevelopment. 20% held by Global Research & Discovery Group LLC (GRDGS) and 10% by ASX-listed Holista CollTech. Tapping GRDGS & Holista expertise, GBLI pledges a concerted effort at prevention and treatment of neurological, oncology and immuno-related diseases. See www.globalbiolife.com.
GRDGS LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, visit www.globalrdg.com.
Singapore eDevelopment (SGX:V40), www.SeD.com.sg or contact@sed.com.sg.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan Apr 26, 2024 10:00 JST
| Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024 Apr 25, 2024 18:21 JST
| MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park Apr 25, 2024 17:45 JST
| GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series Apr 25, 2024 16:50 JST
| Toyota Exhibiting at Beijing Motor Show 2024 Apr 25, 2024 16:25 JST
| Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada Apr 25, 2024 11:10 JST
| UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh Apr 25, 2024 09:00 JST
| Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
| Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
|
More Latest Release >>
|